FDx Advisors Inc. lifted its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 3.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 202,028 shares of the company’s stock after acquiring an additional 7,287 shares during the period. FDx Advisors Inc.’s holdings in Merck & Co., Inc. were worth $12,936,000 at the end of the most recent quarter.
Other hedge funds also recently modified their holdings of the company. Stelac Advisory Services LLC bought a new position in Merck & Co., Inc. in the second quarter valued at $104,000. Perennial Advisors LLC grew its position in Merck & Co., Inc. by 10.7% in the second quarter. Perennial Advisors LLC now owns 1,626 shares of the company’s stock valued at $104,000 after purchasing an additional 157 shares in the last quarter. Cascade Investment Advisors Inc. grew its position in Merck & Co., Inc. by 15.5% in the second quarter. Cascade Investment Advisors Inc. now owns 1,727 shares of the company’s stock valued at $111,000 after purchasing an additional 232 shares in the last quarter. Solaris Asset Management LLC grew its position in Merck & Co., Inc. by 6.3% in the second quarter. Solaris Asset Management LLC now owns 1,940 shares of the company’s stock valued at $124,000 after purchasing an additional 115 shares in the last quarter. Finally, Barnett & Company Inc. grew its position in Merck & Co., Inc. by 481.6% in the second quarter. Barnett & Company Inc. now owns 2,053 shares of the company’s stock valued at $132,000 after purchasing an additional 1,700 shares in the last quarter. 73.63% of the stock is owned by institutional investors.
Shares of Merck & Co., Inc. (MRK) opened at $57.60 on Friday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.16 and a current ratio of 1.43. The stock has a market cap of $157,100.00, a PE ratio of 55.92, a PEG ratio of 2.84 and a beta of 0.76. Merck & Co., Inc. has a 12 month low of $53.63 and a 12 month high of $66.80.
The business also recently announced a quarterly dividend, which was paid on Monday, January 8th. Stockholders of record on Friday, December 15th were paid a dividend of $0.48 per share. This represents a $1.92 dividend on an annualized basis and a dividend yield of 3.33%. The ex-dividend date of this dividend was Thursday, December 14th. This is a boost from Merck & Co., Inc.’s previous quarterly dividend of $0.47. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 186.41%.
Merck & Co., Inc. announced that its board has initiated a share repurchase program on Tuesday, November 28th that authorizes the company to buyback $10.00 billion in shares. This buyback authorization authorizes the company to reacquire shares of its stock through open market purchases. Stock buyback programs are often an indication that the company’s board believes its stock is undervalued.
A number of research firms recently weighed in on MRK. ValuEngine raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research report on Wednesday. BMO Capital Markets set a $68.00 target price on shares of Merck & Co., Inc. and gave the company a “buy” rating in a research report on Wednesday, December 13th. TheStreet downgraded shares of Merck & Co., Inc. from a “b” rating to a “c” rating in a research report on Monday, November 27th. Bank of America initiated coverage on shares of Merck & Co., Inc. in a research report on Tuesday, November 28th. They issued a “buy” rating and a $64.00 target price for the company. Finally, Deutsche Bank decreased their price objective on shares of Merck & Co., Inc. from $62.00 to $59.00 and set a “hold” rating for the company in a research report on Friday, November 24th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and twelve have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $66.29.
In other news, Director Thomas H. Glocer sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $56.20, for a total transaction of $281,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.25% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “FDx Advisors Inc. Raises Stake in Merck & Co., Inc. (MRK)” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://www.com-unik.info/2018/01/12/fdx-advisors-inc-raises-stake-in-merck-co-inc-mrk.html.
Merck & Co., Inc. Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).
What are top analysts saying about Merck & Co. Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Merck & Co. Inc. and related companies.